BioNotebook: Pharmacyclics rises on Imbruvica sales; Allergan eye pact; Progenics, Cytokinetics, Nuvilex raise cash
This article was originally published in Scrip
Executive Summary
The first glimpse of sales for the Pharmacyclics lymphoma and leukemia drug Imbruvica (ibrutinib) sent the Sunnyvale, California-based company's stock up 6.3% for a new high of $151.61 per share on 21 February.